In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids with Eric A. Adams, InMed’s CEO, and Alexandra Mancini, senior VP of clinical and regulatory affairs. The discussion also includes the recent FDA public hearing on cannabidiol (CBD) and its implications for the sector.
What is cannabinol, or CBN? View this infographic to learn four things about cannabinol. Is CBN psychoactive? How is CBN different from THC and CBD?